Asymmetric lacrimal gland enlargement: an indicator for detection of pathological entities other than thyroid eye disease

2018 ◽  
Vol 257 (2) ◽  
pp. 405-411 ◽  
Author(s):  
Eri Ishikawa ◽  
Yasuhiro Takahashi ◽  
Ma. Regina Paula Valencia ◽  
Marian Grace Ana-Magadia ◽  
Hirohiko Kakizaki
Keyword(s):  
Lacrimal Gland ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Gland Enlargement

Recurring thyroid eye disease: a diagnostic dilemma

2015 ◽  
Author(s):  
Pauline McAleer ◽  
Emma Turtle ◽  
Jan Kerr ◽  
Karen Adamson
Keyword(s):  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Diagnostic Dilemma

Early low dose rituximab for active thyroid eye disease: an effective and well tolerated treatment

2018 ◽  
Author(s):  
Elizabeth Insull ◽  
Helen Turner ◽  
Joel David ◽  
Jonathan Norris
Keyword(s):  
Low Dose ◽  
Thyroid Eye Disease ◽  
Eye Disease

Radiotherapy for thyroid eye disease

2001 ◽  
Author(s):  
MJ Wearne ◽  
K Henshaw
Keyword(s):  
Thyroid Eye Disease ◽  
Eye Disease

scholarly journals Assessment of lacrimal glands in thyroid eye disease with diffusion-weighted magnetic resonance imaging

2019 ◽  
Vol 84 ◽  
pp. 142-146 ◽  
Author(s):  
Ahmed Razek ◽  
El-hadidy Mohamed El-Hadidy ◽  
Mohamed El-Said Moawad ◽  
Nader El-Metwaly ◽  
Amr Abd El-hamid El-Said
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Resonance Imaging ◽  
Lacrimal Glands ◽  
Diffusion Weighted ◽  
Weighted Magnetic Resonance Imaging

scholarly journals AB1043 AWARENESS OF THYROID EYE DISEASE, AN AUTOIMMUNE CONDITION, AMONG RHEUMATOLOGISTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1813.1-1813
Author(s):  
B. Lamoreaux ◽  
M. Francis-Sedlak ◽  
R. Holt ◽  
J. Rosenbaum
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Granulomatosis With Polyangiitis ◽  
The United States ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Infusion Therapy ◽  
Graves Disease ◽  
Ocular Motility ◽  
Referral Patterns

Background:Autoimmune inflammatory conditions of the eye may be associated with rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and granulomatosis with polyangiitis. This is also observed with thyroid eye disease (TED). Loss of immune tolerance to the thyroid stimulating hormone receptor has thyroidal consequences and nearly 40% of patients with Graves’ disease also have clinically evident Graves’ orbitopathy or TED.1TED results from tissue inflammation that causes retro orbital fat expansion2and extraocular muscle enlargement2and stiffening.3Because the orbital cavity is bony and of limited volume, proptosis and, in severe cases, optic nerve compression, can result. In many patients, muscle changes also cause ocular motility issues and double-vision. Because TED can have a similar presentation to other inflammatory orbital diseases (e.g., granulomatosis with polyangiitis) and Graves’ disease patients frequently have other autoimmune conditions (10% of Graves’s patients also have rheumatoid arthritis),4rheumatologists are likely to care for, or even diagnose, patients with TED.Objectives:This analysis sought to understand rheumatologists’ knowledge, and degree of participation in the treatment, of TED including referral patterns from ophthalmologists and endocrinologists for infusion therapies.Methods:Rheumatologists practicing in the United States attended an educational session and agreed to complete a 12-item survey regarding TED awareness, referral patterns, and management.Results:Of the 47 rheumatologists surveyed, 45 (96%) were familiar with TED. Ten (21%) physicians reported managing patients with TED, but the majority of physicians (62%) reported that they co-managed other autoimmune diseases in patients who also had TED. Additionally, 98% and 64% of polled rheumatologists had received referrals from ophthalmologists and endocrinologists, respectively, for autoimmune disease management or infusion therapy. Ophthalmology referrals for intravenous (IV) medication administration were most frequently for biologics (82%), but some referrals were also made for corticosteroids (2%) or other medication (13%) infusions. Only 23% of rheumatologists had administered a biologic specifically for TED (rituximab: 17%, tocilizumab: 2%, other: 4%), but 89% expressed an interest in administering a TED-specific monoclonal antibody therapy, awaiting FDA approval.Conclusion:Nearly all surveyed rheumatologists were aware of the signs and symptoms of TED, although most did not actively manage or administer medication for TED. Given the high level of interest in infusing novel, TED-specific biologics, rheumatologists may become an integral part of TED patient management with the approval of a new biologic, teprotumumab, for thyroid eye disease.References:[1]Bartley GB, et al.Am J Ophthalmol1996;121:284-90.[2]Forbes G, et al.AJNR Am J Neuroradiol1986;7:651-656.[3]Simonsz HJ, et al.Strabismus1994;2:197-218.[4]Cardenas Roldan J, et al.Arthritis2012 2012;864907.Disclosure of Interests:Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Megan Francis-Sedlak Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Robert Holt Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, James Rosenbaum Consultant of: AbbVie, Corvus, Eyevensys, Gilead, Novartis, Janssen, Roche, UCB Pharma; royalties from UpToDate

scholarly journals Correlation between uniocular deviation and duction changes following different decompression surgeries in thyroid eye disease

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jie Guo ◽  
Xiaofeng Li ◽  
Ruiqi Ma ◽  
Jiang Qian
Keyword(s):  
Computed Tomography ◽  
Lateral Wall ◽  
Contractile Force ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
Decompression Surgery ◽  
Inferior Wall ◽  
Orbital Decompression ◽  
Significant Difference ◽  
Ocular Deviation

Abstract Background Postoperative ocular imbalance is an important problem for orbital decompression surgery in thyroid eye disease (TED). The aim of this study was to evaluate the changes in unilateral ocular deviation and duction following orbital decompression and discuss the biomechanics of ocular imbalance. Methods Fifty-four TED patients who underwent unilateral orbital decompression were included. Fifteen patients underwent 1-wall (deep lateral wall) decompression, 18 patients underwent 2-wall (deep lateral and medial wall) decompression and 21 patients underwent 3-wall (deep lateral, medial and inferior wall) decompression. Objective and subjective deviation of the operated eyes were evaluated using the prism test and synoptophore, respectively. Ocular ductions were measured using Hirschberg’s method. The diameters of the extraocular rectus were measured by computed tomography. Results Ocular deviation and duction showed no significant difference after 1-wall decompression (p = 0.25–0.89). Esotropia increased after 2-wall decompression (p = 0.001–0.02), and hypotropia increased after 3-wall decompression (p = 0.02). Adduction increased but abduction decreased following 2-wall and 3-wall decompression (p < 0.05). Infraduction increased following 3-wall decompression (p < 0.001). Additionally, the increase in esotropia was significantly correlated with the increase in adduction and with the decrease in abduction (r = 0.37–0.63, p < 0.05). There were significant correlations between the diameter of the medial rectus and the increase in esotropia, the increase in adduction and the decrease in abduction postoperatively (r = 0.35–0.48, p < 0.05). Conclusions The changes in ocular deviation and duction were different after 1-wall, 2-wall and 3-wall orbital decompression. The increased contractile force of the rectus may be an important reason for strabismus changes after orbital decompression surgery.

Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab

2021 ◽  
pp. 112067212199104
Author(s):  
Catherine J Hwang ◽  
Erin E Nichols ◽  
Brian H Chon ◽  
Julian D Perry
Keyword(s):  
Side Effects ◽  
Optic Neuropathy ◽  
Surgical Decompression ◽  
Thyroid Eye Disease ◽  
Eye Disease ◽  
High Dose ◽  
Compressive Optic Neuropathy ◽  
Traditional Management ◽  
Immune Mediated ◽  
Orbital Radiation

Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. The authors report reversal of bilateral dysthyroid compressive optic neuropathy managed medically utilizing teprotumumab.

scholarly journals Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms

2010 ◽  
Vol 55 (3) ◽  
pp. 215-226 ◽  
Author(s):  
Vibhavari M. Naik ◽  
Milind N. Naik ◽  
Robert A. Goldberg ◽  
Terry J. Smith ◽  
Raymond S. Douglas
Keyword(s):  
Thyroid Eye Disease ◽  
Eye Disease
Sign in / Sign up

Export Citation Format

Share Document